Nasal spray COVID vaccine shows promise in new trial

NCT ID NCT05736835

Completed ⭐️ VACCINE ⭐️ Sponsor: CyanVac LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 4 times

Summary

This study tests a new COVID-19 vaccine given as a nasal spray. It aims to see if the spray is safe and helps the body fight the virus. About 227 healthy adults aged 18 to 80 will take part. The vaccine is designed to boost immunity in the nose, where the virus often enters.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
University of Rochester

Rochester, New York, 14642, United States
Velocity Clinical Research

San Diego, California, 91942, United States
Velocity Clinical Research

Boise, Idaho, 83642, United States
Velocity Clinical Research

Sioux City, Iowa, 51106, United States
Velocity Clinical Research

Rockville, Maryland, 20854, United States
Velocity Clinical Research

Omaha, Nebraska, 68134, United States
Velocity Clinical Research

Vestal, New York, 13850, United States
Velocity Clinical Research

Providence, Rhode Island, 02818, United States
Velocity Clinical Research

Cedar Park, Texas, 78759, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.